The benefits of GLP-1 drugs beyond obesity.

Science · 2024

Last updated 2026-05-28

Journal	Science, 2024
Citations	122
Relative citation ratio	20.78
NIH percentile	99
Molecules	—
Conditions studied	Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease, Mash, Obstructive Sleep Apnea, Pcos, Heart Failure, Alcohol Use Disorder, Smoking Cessation, Depression, Anxiety, Fertility

Abstract

Glucagon-like peptide-1-based medicines have weight loss-independent actions.

Verbatim abstract via PubMed 39024455 ↗